Embla Medical hf Beheer

Beheer criteriumcontroles 3/4

De CEO Embla Medical hf is Sveinn Solvason, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.18M, bestaande uit 48.8% salaris en 51.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde DKK 2.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 15.8 jaar.

Belangrijke informatie

Sveinn Solvason

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	48.8%
Dienstverband CEO	2.6yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	15.8yrs

Recente managementupdates

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Apr 10

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Mar 23

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Jan 21

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 03

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Nov 28

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Nov 08

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

Sep 23

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Aug 21

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Jul 18

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 14

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

May 19

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Mar 14

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 21

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

Analyse CEO-vergoeding

Hoe is Sveinn Solvason's beloning veranderd ten opzichte van Embla Medical hf's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$69m
Jun 30 2024	n/a	n/a	US$61m
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$1m	US$576k	US$58m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$45m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$780k	US$409k	US$43m

Compensatie versus markt: De totale vergoeding ($USD 1.18M ) Sveinn } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 1.97M ).

Compensatie versus inkomsten: De vergoeding van Sveinn is het afgelopen jaar met meer dan 20% gestegen.

CEO

Sveinn Solvason (46 yo)

2.6yrs

Tenure

US$1,180,000

Compensatie

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sveinn Solvason	President & CEO	2.6yrs	US$1.18m	0.016% DKK 2.5m
Ossur Kristinsson	Founder	no data	US$25.00k	geen gegevens
Gudny Sveinsdottir	Chief Financial Officer	2.2yrs	geen gegevens	geen gegevens
Lukas Marklin	Chief Operating Officer	1.4yrs	geen gegevens	geen gegevens
Edda Luovigsdottir	Investor Relations Director	no data	geen gegevens	geen gegevens
Margret Fridriksdottir	Executive Vice President of People	no data	US$242.00k	0.0083% DKK 1.3m
Olafur Gylfason	Chief Commercial Officer	no data	US$600.00k	0.0030% DKK 459.8k
Gudjon Karason	Executive Vice President of EMEA & APAC	7yrs	geen gegevens	0.023% DKK 3.5m
Christian Robinson	President of Americas	no data	geen gegevens	0.0031% DKK 473.6k
Hildur Einarsdottir	Executive Vice President of Research & Development	2.6yrs	geen gegevens	0.00014% DKK 21.5k

2.6yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EMBLA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Niels Jacobsen	Chairman of the Board	19.8yrs	US$108.00k	0.048% DKK 7.3m
Svafa Gronfeldt	Vice Chairman of the Board	16.8yrs	US$72.00k	geen gegevens
Gudbjorg Eggertsdottir	Independent Director	11.7yrs	US$43.00k	0.0062% DKK 944.1k
Arne Nielsen	Director	15.8yrs	US$50.00k	geen gegevens
Alberto Esquenazi	Independent Director	3.7yrs	US$43.00k	geen gegevens

15.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EMBLA zijn ervaren en ervaren (gemiddelde ambtstermijn van 15.8 jaar).

Embla Medical hf Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf. Announces Executive Changes

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report